HN2011001697A - Compuesto amino pirazol - Google Patents

Compuesto amino pirazol

Info

Publication number
HN2011001697A
HN2011001697A HN2011001697A HN2011001697A HN2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A HN 2011001697 A HN2011001697 A HN 2011001697A
Authority
HN
Honduras
Prior art keywords
pirazol
amino
compound
meloproliferant
chronic
Prior art date
Application number
HN2011001697A
Other languages
English (en)
Inventor
Paul Burkholder Timothy
Ryan Clayton Joshua
Mia Liandong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011001697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001697A publication Critical patent/HN2011001697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PROVEE COMPUESTOS AMINO PIRAZOL UTILES EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERANTES CRONICOS Y VARIOS CANCERES
HN2011001697A 2008-12-16 2011-06-16 Compuesto amino pirazol HN2011001697A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
HN2011001697A true HN2011001697A (es) 2013-11-26

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001697A HN2011001697A (es) 2008-12-16 2011-06-16 Compuesto amino pirazol

Country Status (39)

Country Link
US (2) US20100286139A1 (es)
EP (1) EP2379557B1 (es)
JP (1) JP5509217B2 (es)
KR (1) KR101300458B1 (es)
CN (1) CN102232075B (es)
AR (1) AR074240A1 (es)
AU (1) AU2009330503B2 (es)
BR (1) BRPI0923048A2 (es)
CA (1) CA2744714C (es)
CL (1) CL2011001445A1 (es)
CO (1) CO6331442A2 (es)
CR (1) CR20110341A (es)
CY (1) CY1113637T1 (es)
DK (1) DK2379557T3 (es)
DO (1) DOP2011000190A (es)
EA (1) EA019554B1 (es)
EC (1) ECSP11011132A (es)
ES (1) ES2396617T3 (es)
HK (1) HK1160109A1 (es)
HN (1) HN2011001697A (es)
HR (1) HRP20120918T1 (es)
IL (1) IL213065A0 (es)
JO (1) JO2833B1 (es)
MA (1) MA32900B1 (es)
MX (1) MX2011006441A (es)
MY (1) MY158691A (es)
NZ (1) NZ592641A (es)
PA (1) PA8851101A1 (es)
PE (1) PE20110549A1 (es)
PL (1) PL2379557T3 (es)
PT (1) PT2379557E (es)
SG (1) SG172202A1 (es)
SI (1) SI2379557T1 (es)
SV (1) SV2011003949A (es)
TN (1) TN2011000292A1 (es)
TW (1) TWI440640B (es)
UA (1) UA104743C2 (es)
WO (1) WO2010074947A1 (es)
ZA (1) ZA201103942B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
BR112013022697A2 (pt) * 2011-03-07 2019-09-24 Fond Telethon inibidores de fosforilação de tfeb e usos dos mesmos
CA2838945A1 (en) * 2011-06-15 2012-12-20 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
US11299494B2 (en) * 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
KR20040068339A (ko) 2001-12-21 2004-07-30 아노르메드 인코포레이티드 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
MX2007009842A (es) 2005-02-16 2007-08-23 Astrazeneca Ab Compuestos quimicos.
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
WO2007005673A1 (en) * 2005-07-01 2007-01-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2624882C (en) * 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CA2624826A1 (en) * 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
CA2667962A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
MX2009012612A (es) 2007-05-23 2009-12-07 Pharmacopeia Llc Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
EP2379557A1 (en) 2011-10-26
US7897600B2 (en) 2011-03-01
EA201170831A1 (ru) 2011-12-30
NZ592641A (en) 2013-01-25
PE20110549A1 (es) 2011-08-04
EP2379557B1 (en) 2012-10-31
CA2744714A1 (en) 2010-07-01
KR101300458B1 (ko) 2013-08-30
JP5509217B2 (ja) 2014-06-04
AU2009330503B2 (en) 2012-06-07
DOP2011000190A (es) 2011-07-31
IL213065A0 (en) 2011-07-31
US20100286139A1 (en) 2010-11-11
DK2379557T3 (da) 2012-12-17
CR20110341A (es) 2011-07-13
AR074240A1 (es) 2011-01-05
EA019554B1 (ru) 2014-04-30
PT2379557E (pt) 2013-01-14
JP2012512158A (ja) 2012-05-31
US20100152181A1 (en) 2010-06-17
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
PL2379557T3 (pl) 2013-03-29
ES2396617T3 (es) 2013-02-22
CN102232075A (zh) 2011-11-02
SI2379557T1 (sl) 2013-02-28
WO2010074947A1 (en) 2010-07-01
CY1113637T1 (el) 2016-06-22
HRP20120918T1 (hr) 2012-12-31
TN2011000292A1 (en) 2012-12-17
SG172202A1 (en) 2011-07-28
CO6331442A2 (es) 2011-10-20
PA8851101A1 (es) 2010-07-27
AU2009330503A1 (en) 2010-07-01
MY158691A (en) 2016-10-31
ZA201103942B (en) 2012-08-29
CN102232075B (zh) 2013-12-11
MX2011006441A (es) 2011-07-19
TW201024301A (en) 2010-07-01
ECSP11011132A (es) 2011-07-29
CA2744714C (en) 2013-06-25
TWI440640B (zh) 2014-06-11
BRPI0923048A2 (pt) 2018-09-25
HK1160109A1 (en) 2012-08-10
CL2011001445A1 (es) 2011-11-11
KR20110084993A (ko) 2011-07-26
JO2833B1 (en) 2014-09-15
UA104743C2 (ru) 2014-03-11

Similar Documents

Publication Publication Date Title
HN2011001697A (es) Compuesto amino pirazol
CR20110580A (es) Compuestos vinil indazolilo
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201170832A1 (ru) Пуриновые соединения
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
UY31432A1 (es) Compuestos de diarilhidantoina
DK2478907T3 (da) Sammensætninger til behandling af kræft
MA32938B1 (fr) Composes organiques
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
GT201100181A (es) "inhibidores de proteina cinasa"
CR20130045A (es) Compuestos terapéuticos
BRPI0821779A2 (pt) tratamento terapêutico de câncer
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
NL2000439A1 (nl) Therapeutische toepassingen van inhibitoren van RTP801.
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
CR20120303A (es) Tratamientos para trastornos gastrointestinales
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
DOP2005000010A (es) Inhibidores de quinasa
DK2219683T3 (da) Målrettet radioterapi
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
SMT201600156B (it) Trattamento dell’osteoartrite
EP2225196A4 (en) CYSTONE PROTEASE INHIBITOR FOR THE TREATMENT OF PARASITIC DISEASES